Paradigm Biopharmaceuticals Limited (PAR) Fair Value & Analysis
Healthcare · AU · Market cap A$83.6M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.1700 to A$0.1048 (−38.4%) since Jun 24, 2026. Share price −11.4% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.1445 – A$0.4800 · fair‑value band A$0.0625 – A$0.1365 · the A$0.1600 price screens above the A$0.1048 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Paradigm Biopharmaceuticals Limited (PAR) currently trades at A$0.1600, while our model-based Fair Value estimate is A$0.1048 — implying the stock looks roughly 34.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$8.5K. Revenue grew 50.6% year over year. The balance sheet holds a net cash position of A$16.8M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Paradigm Biopharmaceuticals Limited reported revenue of A$52.1K in FY2025 versus A$20.6K in FY2021, a compound +26.2%/yr. Reported net income was −A$18.8M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Paradigm Biopharmaceuticals Limited (PAR) undervalued?
What is the fair value of PAR?
What is the quality score of PAR?
What is the revenue of Paradigm Biopharmaceuticals Limited (PAR)?
What is the net profit margin of PAR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.